Drug class profile · refreshed daily from federal data

Barbiturate

8 molecules in this class, combined CY2024 Part D spend across claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Barbiturate class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
8tracked in Part D
CY24 Part D spend
combined across class
Total Rx claims
— unique beneficiaries
Generic mfrs (active)
25across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Butal/Apap/Caff
Part D claims (CY24) · First FDA approval:
Brand-only (no generics)
Low NADAC
Avg plan cost
Part D spend  
Class share
0%
of class CY24 spend
View profile →
02
Butal/Apap/Caffeine
Part D claims (CY24) · First FDA approval:
Brand-only (no generics)
Low NADAC
Avg plan cost
Part D spend  
Class share
0%
of class CY24 spend
View profile →
03
Butalbital and Acetaminophen
Brand: ALLZITAL · Part D claims (CY24) · First FDA approval:
8 generic mfrs 27 plans require PA
Low NADAC$0.578
Avg plan cost$0.896
Part D spend spread, current vs floor
Class share
0%
of class CY24 spend
View profile →
04
Butalbital and Acetaminophen Tablets
Brand: Butalbital and Acetaminophen · Part D claims (CY24) · First FDA approval:
Brand-only (no generics)
Low NADAC
Avg plan cost
Part D spend  
Class share
0%
of class CY24 spend
View profile →
05
Butalbital, Acetaminophen and Caffeine
Part D claims (CY24) · First FDA approval:
15 generic mfrs 83 plans require PA
Low NADAC$0.122
Avg plan cost$0.663
Part D spend spread, current vs floor
Class share
0%
of class CY24 spend
View profile →
07
Butalbital, Acetaminophen, and Caffeine Capsules
Brand: Butalbital, Acetaminophen, and Caffeine · Part D claims (CY24) · First FDA approval:
Brand-only (no generics)
Low NADAC$0.336
Avg plan cost$0.336
Part D spend spread, current vs floor
Class share
0%
of class CY24 spend
View profile →